- In March 2026, Thermo Fisher Scientific announced a collaboration with SHL Medical to build an integrated U.S. hub in Ridgefield for sterile fill-finish, autoinjector assembly, and commercial packaging of patient-friendly injectable therapies, complementing its global sterile manufacturing network.
- This move deepens Thermo Fisher’s role as an end-to-end partner for pharma and biotech customers by linking drug manufacturing directly to finished self-injection devices in a single, scalable platform.
- We’ll now explore how integrating SHL Medical’s Molly autoinjector platform into Thermo Fisher’s U.S. sterile network could reshape its investment narrative.
Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
Thermo Fisher Scientific Investment Narrative Recap
To own Thermo Fisher Scientific, you need to believe in its role as a global, end-to-end enabler of drug development, manufacturing, and diagnostics. The SHL Medical collaboration supports that thesis by tightening its grip on injectable therapies, but it does not fundamentally change the near term balance between pharma-driven strength and ongoing pressure from weaker academic and government demand or China exposure.
Among recent developments, the acquisition and build-out of the Ridgefield site from Sanofi in 2025 is most relevant here, because it underpins Thermo Fisher’s push into integrated sterile fill-finish and device assembly. Together with the SHL partnership, it reinforces one of the clearest current catalysts: deeper involvement in high value biopharma services, while still leaving investors exposed to external risks like tariffs and policy shifts.
Yet, behind this attractive end-to-end story, investors should also be aware of growing dependence on acquisitions and the risks if expected integration benefits...
Read the full narrative on Thermo Fisher Scientific (it's free!)
Thermo Fisher Scientific's narrative projects $50.0 billion revenue and $9.0 billion earnings by 2028. This requires 5.0% yearly revenue growth and a $2.4 billion earnings increase from $6.6 billion.
Uncover how Thermo Fisher Scientific's forecasts yield a $663.96 fair value, a 38% upside to its current price.
Exploring Other Perspectives
Compared with consensus, the most optimistic analysts already expected revenue of about US$52.7 billion and earnings near US$9.5 billion by 2028, so this new SHL collaboration could either support that upside story or expose how sensitive those forecasts are to issues like acquisition integration and trade frictions.
Explore 10 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth 15% less than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Thermo Fisher Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance.
Interested In Other Possibilities?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Find 62 companies with promising cash flow potential yet trading below their fair value.
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com